IP Library Granted Patent US 11,529,447
Granted Patent B2
US 11,529,447 · App. 16/857,782 · Granted Dec 20, 2022

Method for peritoneal removal of electrolytes and inflammatory mediators

Inventors: Ian Stewart (Lodi, CA); Jonathan Sosnov (San Antonio, TX); James Ross (Portland, OR)
Assignee: United States of America as represented by the Secretary of the Air Force
A61M1/285A61M1/28A61M1/287B01D15/34A61M2202/0468A61M2205/04A61M2205/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,529,447
App. No.
16/857,782
Granted
Dec 20, 2022
Kind
B2
Abstract

A method of peritoneal removal of electrolytes and inflammatory mediators. The method begins with infusing a treatment solution into the peritoneal cavity of a patient by way of a catheter. The treatment solution is drained from the peritoneal cavity by way of the catheter. During the draining, the treatment solution is filtered for removing electrolytes and inflammatory mediators.

Claims (11)

1. A method of peritoneal removal of electrolytes and inflammatory mediators, the method comprising:

implanting a filter cartridge in the peritoneal cavity of a patient;

infusing a treatment solution into the peritoneal cavity of a patient; and

drawing the treatment solution from the peritoneal cavity through the filter cartridge and pulling the treatment solution from the peritoneal cavity by way of a wound drain;

wherein the filter cartridge comprises a binding agent enclosed within a porous surgical packing material.

2. The method of claim 1 , wherein the wound drain is fluidically coupled to a pump.

3. The method of claim 1 , further comprising:

re-instilling the treatment solution into the peritoneal cavity.

4. The method of claim 1 , wherein the binding agent is configured to selectively bind electrolytes, inflammatory mediators, or both.

5. The method of claim 4 , wherein the binding agent is selected from the group consisting of:

a polymer, a resin, or diffusion tubes configured to remove inflammatory mediators.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2023
From: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE
To: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE DIRECTOR OF THE DEFENSE HEALTH AGENCY
Reel/Frame 064451/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2022
From: STEWART, IAN; ROSS, JAMES; SOSNOV, JONATHAN
To: THE GOVERNMENT OF THE UNITED STATES AS REPRSENTED BY THE SECRETARY OF THE AIR FORCE
Reel/Frame 062141/0967 →
Continuity (3)
Division 15783094 · Nov 13, 2017
Provisional Application 62410136 · Oct 19, 2016
Related Publication 20200254168A1 · Aug 13, 2020